OncoSec Medical Incorporated
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert H. Arch
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 24 North Main Street Pennington NJ United States of America 08534
- IPO Date
- Apr 7, 2010
- CIK
- 0001444307
- Website
- oncosec.com
- Similar Companies
- Business
- OncoSec Medical Incorporated, a late-stage immuno-oncology biotechnology company, focuses on designing, developing, and commercializing proprietary intra-tumoral DNA-based immunotherapies delivered via electroporation to stimulate anti-tumor immune responses in patients with solid tumors. Founded in 2011 and headquartered in San Diego, California, the company leverages its ImmunoPulse platform, featuring the OMS electroporation device paired with DNA plasmids; its lead candidate, TAVO (tavokinogene telseplasmid), encodes interleukin-12 (IL-12) for intratumoral delivery to reverse tumor immunosuppression and elicit systemic immunity, targeting cancers including metastatic melanoma, triple-negative breast cancer (via KEYNOTE-890 trial), Merkel cell carcinoma, squamous cell carcinoma, and others in ongoing Phase II trials like KEYNOTE-695. The pipeline also encompasses combinations such as TAVO with checkpoint inhibitors (pembrolizumab, nivolumab), epacadostat, CXCL9 plasmids, and investigational OMS-100/OMS-102 plasmids for melanoma; operations historically spanned the United States, Australia (via former subsidiary OncoSec Medical Australia), and global clinical collaborations with Merck & Co. In June 2023, OncoSec filed for voluntary Chapter 7 bankruptcy liquidation in the US Bankruptcy Court for the District of Delaware, listing $0.95 million in assets against $10.32 million in liabilities, leading to Nasdaq delisting, subsidiary wind-down under Australian law, and trustee oversight of asset liquidation; prior to this, it received $3.49 million in non-dilutive New Jersey tax credits in April 2023 from selling net operating loss carryforwards and closed a $1.33 million registered direct offering, with its website now addressing Chapter 7 FAQs amid halted active development.
Why Is OncoSec Medical (ONCS) Stock Up 100% Today?
Why Is OncoSec Medical (ONCS) Stock Down 48% Today?
3 Top Penny Stocks To Watch After Big News This Week
Avoid Common Penny Stocks Trading Mistakes With These Tips
ONCS Stock: Over 120% Surge Explantion
Why is OncoSec Medical (ONCS) Stock Up 91% Today?
Why Is OncoSec Medical (ONCS) Stock Down 25% Today?
Top 5 most-shorted stocks as of December 2022
ONCS Stock Alert: What to Know About OncoSec Medical as It Drops Today
OncoSec Announces Pipeline Prioritization and Workforce Reduction
5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
Top Penny Stocks to for Your Buy List Right Now? Here's 9 to Watch
OncoSec Medical Stock Increases Over 25% Pre-Market: Why It Happened
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
OncoSec to Present at the Raymond James Human Health Innovation Conference
OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma